Publications

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Obesity Imaging Whitepaper

Author:

Perspectum

Journal:

Internal

Publication Year:

2025

Technologies:

Pharma Solutions

Repeatability, Reproducibility, and Observer Variability of Cortical T1 Mapping for Renal Tissue Characterization

Author:

Nowak et al.

Journal:

JMRI

Publication Year:

2024

Technologies:

CoverScan

Feasibility of using contrast-free quantitative magnetic resonance imaging for liver sparing stereotactic ablative body radiotherapy

Author:

Brewer et al

Journal:

clinical and translational radition oncology

Publication Year:

2024

Technologies:

Hepatica

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Author:

Loomba et al.,

Journal:

The New England Journal of Medicine

Publication Year:

2024

Technologies:

LiverMultiScan

Decreases in cT1 and liver fat content accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled analysis.

Author:

Alkhouri et al,

Journal:

Journal of Hepatology

Publication Year:

2024

Technologies:

LiverMultiScan

Quantitative MRI as a tool for monitoring metabolic dysfunction-associated steatotic liver disease: A test-retest repeatability study.

Author:

Beyer et al.,

Journal:

JMRI

Publication Year:

2024

Technologies:

LiverMultiScan

Quantitative Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Autoimmune Hepatitis.

Author:

Socha et al.,

Journal:

Journal of Pathology Informatics.

Publication Year:

2024

Technologies:

Digipath

Novel multimetric MRI detects improved future liver remnant quality post-dual vein embolization

Author:

Sundaravadanan et al.,

Journal:

Journal of the International Hepato-Pancreato-Biliary Association

Publication Year:

2024

Technologies:

Hepatica

Quantitative Imaging Reveals Steatosis and Fibroinflammation in Multiple Organs in People With Type 2 Diabetes: A Real-World Study

Author:

Diamond et al.

Journal:

Diabetes

Publication Year:

2024

Technologies:

CoverScan

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.

Author:

Bowlus et al.,

Journal:

Hepatology

Publication Year:

2023

Technologies:

MRCP+

Randomized, Controlled Trial of the FGF21 Analogie Pegozafermin in NASH

Author:

Loomba et al.,

Journal:

The New England Journal of Medicine

Publication Year:

2023

Technologies:

LiverMultiScan

Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study

Author:

Roca-Fernandez et al.,

Journal:

Journal of Hepatology

Publication Year:

2023

Technologies:

LiverMultiScan

Corrected T1 Mapping in Children and Young Adults With Autoimmune Liver Disease: Correlation With Histology.

Author:

Trout et al.,

Journal:

American Journal of Roentgenology

Publication Year:

2023

Technologies:

LiverMultiScan

Cardiac abnormalities in Long Covid 1-year post-SARS-CoV-2 infection: a prospective cohort study.

Author:

Roca-Fernandez et al.,

Journal:

Open Heart

Publication Year:

2023

Technologies:

LiverMultiScan

CoverScan

Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.

Author:

Dichtel et al,

Journal:

J Clin Endocrinol Metab.

Publication Year:

2023

Technologies:

LiverMultiScan

Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis.

Author:

Johannes et al,

Journal:

Liver Int.

Publication Year:

2023

Technologies:

LiverMultiScan

Diagnosis and management of autoimmune hepatitis.

Author:

Muratori et al.,

Journal:

BMJ

Publication Year:

2023

Technologies:

LiverMultiScan

A Snapshot of Digital Transformation in Hepatology and Rare Liver Disease Related Health Care: A UK Perspective.

Author:

Ala et al,

Journal:

Mayo Clinic Proceedings: Digital Health

Publication Year:

2023

Technologies:

LiverMultiScan

MRCP+

Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why.

Author:

Dennis,

Journal:

Translational Gastroenterology and Hepatology

Publication Year:

2023

Technologies:

LiverMultiScan

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future.

Author:

Yip et al,

Journal:

Clin Mol Hepatol

Publication Year:

2023

Technologies:

LiverMultiScan

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.

Author:

Ratziu et al,

Journal:

J Hepatol.

Publication Year:

2023

Technologies:

LiverMultiScan

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Author:

Rinella et al,

Journal:

Hepatology

Publication Year:

2023

Technologies:

LiverMultiScan

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Author:

Loomba et al,

Journal:

N Engl J Med.

Publication Year:

2023

Technologies:

LiverMultiScan

Bayesian networks and imaging-derived phenotypes highlight the role of fat deposition in COVID-19 hospitalisation risk.

Author:

Waddell et al,

Journal:

Front Bioinform.

Publication Year:

2023

Technologies:

CoverScan

Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection.

Author:

Roca-Fernandez et al.,

Journal:

Open Heart

Publication Year:

2023

Technologies:

CoverScan

Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study.

Author:

Dennis et al,

Journal:

J R Soc Med.

Publication Year:

2023

Technologies:

CoverScan

Clonal hematopoiesis and risk of chronic liver disease.

Author:

Wong et al.,

Journal:

Nature

Publication Year:

2023

Technologies:

LiverMultiScan

To pay or not to pay for artificial intelligence applications in radiology.

Author:

Lobig et al,

Journal:

NPJ Digit Med.

Publication Year:

2023

Technologies:

Digipath

Atlas

Pharma Solutions

CoverScan

Hepatica

Prognostic models and autoimmune liver diseases.

Author:

D'Amato & Carbone,

Journal:

Best Pract Res Clin Gastroenterol.

Publication Year:

2023

Technologies:

LiverMultiScan

Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.

Author:

Waddell et al,

Journal:

Front Endocrinol (Lausanne).

Publication Year:

2023

Technologies:

LiverMultiScan

CoverScan

Bayesian-networks and imaging derived phenotypes highlight the role of fat deposition on hospitalisation risk with COVID-19.

Author:

Waddell et al.,

Journal:

Frontiers in Bioinformatics

Publication Year:

2023

Technologies:

CoverScan

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & Validation of Imaging Modality Performance across the NAFLD Spectrum in a Prospectively Recruited Cohort Study (The LITMUS Imaging Study): Study Protocol.

Author:

Pavlides et al.,

Journal:

Contemporary Clinical Trials

Publication Year:

2023

Technologies:

LiverMultiScan

Cardiovascular imaging in the integrated assessment of metabolic health

Author:

Thomaides-Brears et al.,

Journal:

Frontiers in Cardiovascular Medicine

Publication Year:

2023

Technologies:

CoverScan

A low energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis

Author:

Koutoukidis et al.,

Journal:

Obesity

Publication Year:

2023

Technologies:

LiverMultiScan

Editorial: Cardiovascular imaging in the integrated assessment of metabolic health.

Author:

Thomaides-Brears & Banerjee,

Journal:

Front Cardiovasc Med.

Publication Year:

2023

Technologies:

CoverScan

Multi-organ impairment and Long COVID: a 1-year prospective, logitudinal cohort study

Author:

Dennis et al.,

Journal:

Journal of the Royal Society of Medicine

Publication Year:

2023

Technologies:

CoverScan

Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Elastography to evaluate the early effects of bariatric surgery on non-alcoholic liver disease

Author:

Tan et al.,

Journal:

International Journal of Biomedical Imaging

Publication Year:

2023

Technologies:

LiverMultiScan

Association of chronic liver disease with cardiovascular outcomes in 33,616 individuals in a prospective UK Biobank study

Author:

Roca-Fernandez et al.,

Journal:

Journal of Hepatology

Publication Year:

2023

Technologies:

LiverMultiScan

Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Author:

Tincopa & Loomba,

Journal:

The Lancet: Gastroenterology & Hepatology

Publication Year:

2023

Technologies:

LiverMultiScan

A Composite Score Using Quantitative Magnetic Resonance Cholangiopancreatography Predicts Clinical Outcomes in Primary Sclerosing Cholangitis

Author:

Vuppalanchi et al.,

Journal:

JHep Reports

Publication Year:

2023

Technologies:

MRCP+

Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type-2 diabetes: insights from Bayesian-network modelling

Author:

Waddell et al.,

Journal:

Frontiers in Endocrinology

Publication Year:

2023

Technologies:

CoverScan

Quantitative MRCP-derived PSC (qMRCP-PSC) score: an artificial-intelligence derived model for medium-term outcome prediction in primary sclerosing cholangitis

Author:

Cristoferi et al.,

Journal:

Digestive and Liver Disease

Publication Year:

2023

Technologies:

MRCP+

The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.

Author:

Kugelmas et al.,

Journal:

Liver International

Publication Year:

2023

Technologies:

LiverMultiScan

Longitudinal Changes in Quantitative Magnetic Resonance Imaging Metrics in Children and Young Adults with Autoimmune Liver Disease

Author:

Mahalingam et al.,

Journal:

Journal of Abdominal Radiology

Publication Year:

2023

Technologies:

MRCP+

LiverMultiScan

Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing (Precision1 trial): Study protocol for observational cohort study.

Author:

Welsh et al.,

Journal:

BMJ Open

Publication Year:

2022

Technologies:

Hepatica

A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population.

Author:

Seidelin et al

Journal:

Hepatology international

Publication Year:

2022

Technologies:

LiverMultiScan

Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes.

Author:

Waddell et al,

Journal:

Obesity (Silver Spring)

Publication Year:

2022

Technologies:

Hepatica

Greater ectopic fat deposition, liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes

Author:

Waddell et al

Journal:

Obesity

Publication Year:

2022

Technologies:

LiverMultiScan

CoverScan

Pancreas MRI segmentation into head, body, and tail enables regional quantitative analysis of heterogeneous disease

Author:

Triay Bagur et al

Journal:

Journal of Magnetic Resonance Imaging

Publication Year:

2022

Technologies:

MRCP+

4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion.

Author:

Rijnberg et al

Journal:

Journal of Cardiovascular Magnetic Resonance

Publication Year:

2022

Technologies:

MRCP+

LiverMultiScan

An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.

Author:

Ratziu et al.,

Journal:

Hepatology

Publication Year:

2022

Technologies:

LiverMultiScan

NALFD and NASH Biomarker Qualification in the LITMUS consortium – Lessons learned

Author:

Rasmussen et al.,

Journal:

Journal of Hepatology

Publication Year:

2022

Technologies:

LiverMultiScan

AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

Author:

Long et al.,

Journal:

Gastroenterology

Publication Year:

2022

Technologies:

LiverMultiScan

Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants.

Author:

McCracken et al.,

Journal:

Nature Communications

Publication Year:

2022

Technologies:

LiverMultiScan

Associations between Quantitative MRI and Clinical Risk Scores in Children & Young Adults with Autoimmune Liver Disease

Author:

McCrary et al

Journal:

American Journal of Roentgenology

Publication Year:

2022

Technologies:

MRCP+

LiverMultiScan

Genetic Variants of Glycogen Metabolism Genes Were Associated With Liver PDFF Without Increasing NAFLD Risk.

Author:

Liu et al

Journal:

Frontiers in Genetics

Publication Year:

2022

Technologies:

LiverMultiScan

Quantitative MR in paediatric patients with Wilson disease: a case series review.

Author:

Janowski et al.

Journal:

Children

Publication Year:

2022

Technologies:

MRCP+

LiverMultiScan

Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis

Author:

Heneghan et al.,

Journal:

eClinicalMedicine

Publication Year:

2022

Technologies:

LiverMultiScan

Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B.

Author:

Hui et al.,

Journal:

Journal of Gastroenterology and Hepatology

Publication Year:

2022

Technologies:

LiverMultiScan

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

Author:

Cusi et al.,

Journal:

Endocrine Practice

Publication Year:

2022

Technologies:

LiverMultiScan

Quantitative magnetic resonance cholangiography derived biliary metrics are associated with disease severity and clinical outcomes in patients with Primary Sclerosing Cholangitis

Author:

Cazzagon et al.,

Journal:

JHEP Reports

Publication Year:

2022

Technologies:

MRCP+

The Additive Value of Cardiovascular Magnetic Resonance in Convalescent COVID-19 Patients.

Author:

Borlotti et al,

Journal:

Front Cardiovasc Med

Publication Year:

2022

Technologies:

CoverScan

LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England; an economic evaluation

Author:

Bajre et al.,

Journal:

BMJ Open

Publication Year:

2022

Technologies:

LiverMultiScan

Technology-enabled, evidence-driven and patient-centered: the way forward for software as a medical device.

Author:

Carolan et al.

Journal:

Journal of Medical Internet Research (JMIR Medical Informatics)

Publication Year:

2022

Technologies:

Digipath

Atlas

Pharma Solutions

CoverScan

Hepatica

Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers

Author:

Basu et al.

Journal:

Mayo Clinic Proceeedings

Publication Year:

2022

Technologies:

LiverMultiScan

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

Author:

Harrison, S., et al.

Journal:

The American Journal of Gastroenterology

Publication Year:

2021

Technologies:

LiverMultiScan

A quantitative MRCP metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis

Author:

Selvaraj et al.,

Journal:

Hepatology Communication

Publication Year:

2021

Technologies:

MRCP+

Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis.

Author:

Thomaides-Brears et al.,

Journal:

Digestive Diseases and Sciences

Publication Year:

2021

Technologies:

LiverMultiScan

Quantitative multiparametric MRI allows safe surgical planning in patients undergoing liver resection for colorectal liver metastases: report of two patients.

Author:

Sethi et al.,

Journal:

British Journal of Radiology Case Reports

Publication Year:

2021

Technologies:

Hepatica

Hepatic Steatosis Rather Than Underlying Obesity Confers a Higher Risk of Testing Positive and Increases the Risk of Hospitalization For COVID-19.

Author:

Roca-Fernandez et al.,

Journal:

Frontiers in Medicine (Gastroenterology)

Publication Year:

2021

Technologies:

LiverMultiScan

A 3D Quantitative MRC Modeling Images Detected Case of Intrahepatic Biliary Stricture Diseases

Author:

Nanashima et al.,

Journal:

Case Rep Gastroenterology

Publication Year:

2021

Technologies:

MRCP+

Repeatability and reproducibility of deep-learning based liver volume and Couinaud segment volume measurement tool.

Author:

Mojtahed et al.,

Journal:

Abdominal Radiology

Publication Year:

2021

Technologies:

Hepatica

Multiparametric MRI imaging, autoimmune hepatitis, and prediction of disease activity.

Author:

Arndtz et al

Journal:

Hepatology Communications

Publication Year:

2021

Technologies:

LiverMultiScan

Patient Understanding and Experience of Non-invasive Liver Diagnostic Techniques and the Liver Patient Pathway: A Qualitative Study.

Author:

McKay et al.,

Journal:

Submitted to Research Involvement and Engagement

Publication Year:

2021

Technologies:

LiverMultiScan

Associations between MRI T1 Mapping, Liver Stiffness, Quantitative MRCP, and Laboratory Biomarkers in Children and Young Adults with Autoimmune Liver Disease

Author:

Mahalingam et al

Journal:

Abdominal Radiology

Publication Year:

2021

Technologies:

MRCP+

LiverMultiScan

Comparison of quantitative 3D magnetic resonance cholangiography measurements obtained using three different image acquisition methods

Author:

Mahalingam et al

Journal:

Abdominal Radiology

Publication Year:

2021

Technologies:

MRCP+

Quantitative multiparametric MRI as a non-invasive tool stratification in autoimmune liver disease.

Author:

Janowski et al.,

Journal:

Sci Reports

Publication Year:

2021

Technologies:

MRCP+

LiverMultiScan

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance

Author:

Johnson et al.,

Journal:

JHepReports

Publication Year:

2021

Technologies:

LiverMultiScan

Evaluation of Quantitative MRCP (MRCP+) for Risk Stratification of Primary Sclerosing Cholangitis: Comparison with Morphological MRCP, MR Elastography and Biochemical Risk Scores.

Author:

Ismail et al.,

Journal:

European Radiology

Publication Year:

2021

Technologies:

MRCP+

Quantitative multiparametric MRI can aid NASH diagnosis in a Japanese cohort.

Author:

Imajo et al.,

Journal:

World Journal of Gastroenterology

Publication Year:

2021

Technologies:

LiverMultiScan

Prospective Evaluation of the Prevalence of Nonalcoholic Fatty Liver Disease and Steatohepatitis in a Large Middle-Aged United States Cohort.

Author:

Harrison et al.,

Journal:

Journal of Hepatology

Publication Year:

2021

Technologies:

LiverMultiScan

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study.

Author:

Dennis et al.,

Journal:

BMJ Open

Publication Year:

2021

Technologies:

Atlas

Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis.

Author:

Dennis et al.

Journal:

Frontiers of Endocrinology

Publication Year:

2021

Technologies:

LiverMultiScan

Non-alcoholic fatty liver disease: A patient guideline.

Author:

Francque et al.,

Journal:

JHep Reports

Publication Year:

2021

Technologies:

LiverMultiScan

Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A pooled data and meta-analysis.

Author:

Andersson et al.,

Journal:

Clinical Gastroenterology and Hepatology

Publication Year:

2021

Technologies:

LiverMultiScan

Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH randomised, controlled trial.

Author:

Amerikanou et al.,

Journal:

Molecular Nutrition and Food Research

Publication Year:

2021

Technologies:

LiverMultiScan

Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort.

Author:

Beyer et al.,

Journal:

PLOS One

Publication Year:

2021

Technologies:

LiverMultiScan

Segmenting Hepatocellular Carcinoma in Multi-phase CT. MIUA 2020.

Author:

Vogt et al.,

Journal:

Communications in Computer and Information Science

Publication Year:

2020

Technologies:

Hepatica

rs641738C>T near MBOAT7 promotes steatosis, NASH, fibrosis and hepatocellular carcinoma in non-alcoholic fatty liver disease: a meta-analysis.

Author:

Teo et al.

Journal:

Journal of Hepatology

Publication Year:

2020

Technologies:

LiverMultiScan

Multiparametric MR mapping in clinical decision-making for diffuse liver disease.

Author:

Thomaides-Brears et al.

Journal:

Abdominal Radiology

Publication Year:

2020

Technologies:

LiverMultiScan

The Effect of Multiparametric Magnetic Resonance Imaging in Standard of Care for Non-alcoholic Fatty Liver Disease: Protocol for a Randomised Control Trial.

Author:

Tonev at al,

Journal:

JMIR Research Protocols

Publication Year:

2020

Technologies:

LiverMultiScan

Genome wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis

Author:

Parisinos, C.A., et al.

Journal:

Journal of Hepatology

Publication Year:

2020

Technologies:

LiverMultiScan

Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.

Author:

Schaapman et al

Journal:

JMRI

Publication Year:

2020

Technologies:

LiverMultiScan

Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer.

Author:

Mole et al.

Journal:

PLOS ONE

Publication Year:

2020

Technologies:

Hepatica

Liver cT1 decreases following direct acting antiviral therapy in patients with chronic hepatitis C virus – a prospective observational cohort study.

Author:

Jayaswal et al.

Journal:

Abdominal Imaging

Publication Year:

2020

Technologies:

LiverMultiScan

Multiparametric MRI as a non-invasive monitoring tool for children with autoimmune liver disease.

Author:

Janowski et al.,

Journal:

JPGN

Publication Year:

2020

Technologies:

LiverMultiScan

Prognostic value of multiparametric MRI, transient elastography and blood-based fibrosis markers in patients with chronic liver disease

Author:

Jayaswal et al.

Journal:

Liver International

Publication Year:

2020

Technologies:

LiverMultiScan

Serum Matrix Metalloproteinase 7 (MMP7) is a biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease.

Author:

Lam et al.

Journal:

J Hepatology

Publication Year:

2020

Technologies:

MRCP+

Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes.

Author:

Hydes et al.

Journal:

Diabetic Medicine

Publication Year:

2020

Technologies:

LiverMultiScan

Relationship between magnetic resonance imaging spleen T1 relaxation and other radiologic and clinical biomarkers of liver fibrosis in children and young adults with autoimmune liver disease.

Author:

Dillman et al.

Journal:

Abdominal MRI

Publication Year:

2020

Technologies:

LiverMultiScan